Photoimmunotherapy for Local Recurrence of Nasopharyngeal Carcinoma: A Case Report

Photoimmunotherapy (PIT), developed by the National Cancer Institute, involves Cetuximab sarotalocan sodium infusion followed laser irradiation. PIT exerts specific antitumor effects on a variety of carcinomas that express epidermal growth factor receptors. is new cancer treatment option approved Japan ahead other countries worldwide. As 2022, indicated in “unresectable, locally advanced, or recurrent head and neck cancer, with priority given to standard treatments such as chemotherapy when available”. The conventional for unresectable advanced palliative. Whether photoimmunotherapy can be curative cancers depends case. Herein, we report case nasopharyngeal carcinoma, treated via nasal cavity, along literature review. Preoperative simulation provided considerable information device selection, numbers devices, availability working space. result, complete response was obtained following cylindrical diffuser puncture. Cases local recurrence carcinoma are considered good indication PIT. However, since follow-up period after short this case, will continue conduct strict follow-ups accumulate more cases.